A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2014 - September 24, 2019